News Releases

Year

Jul 06, 2023

UroGen Pharma to Host UGN-102 Data Event on July 27, 2023

-- Program to Highlight Topline Results from the Phase 3 ATLAS and Pivotal ENVISION Clinical Trials -- PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 6, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and

Jun 20, 2023

Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration

PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 20, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first post-commercial

Jun 09, 2023

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 9, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 6 new

Jun 02, 2023

UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 2, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in June:

May 11, 2023

UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Reported JELMYTO ® Q1 2023 net product revenues of $17.2 million , an increase of ~27% from Q1 2022 Complete Response data from ENVISION pivotal trial and topline data readout from ATLAS trial on track for summer 2023 PRINCETON, N.J. --(BUSINESS WIRE)--May 11, 2023-- UroGen Pharma Ltd.

May 04, 2023

UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023

Conference Call and Webcast Scheduled for Thursday, May 11, 2023 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--May 4, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today

May 01, 2023

First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation

New Retrospective Study Presented at AUA 2023 Reports Use of JELMYTO in Treating Patients with Upper Tract Urothelial Cancer After Complete Endoscopic Ablation PRINCETON, N.J. --(BUSINESS WIRE)--May 1, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and

Apr 30, 2023

New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis

PRINCTON, N.J.--(BUSINESS WIRE)--Apr. 30, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest

Apr 25, 2023

UroGen Pharma to Present at H.C. Wainwright BioConnect Conference

- Fireside Chat May 2, 2023 from 10:00 – 10:30 AM ET - PRINCETON, N.J. --(BUSINESS WIRE)--Apr. 25, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will

Mar 16, 2023

UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments

Reported JELMYTO® full year 2022 net product revenues of $64.4 million , an increase of 34% from full year 2021 Completed enrollment of the ENVISION Phase 3 pivotal clinical trial for UGN-102 for LG-IR-NMIBC Topline data readout from ATLAS clinical study and Complete Response from ENVISION pivotal

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on